Valued at USD 3.86 billion in 2022, the market for unstable angina therapeutics is foreseen to increase to USD 4.05 billion in FY 2023, representing a Y-o-Y increase of 4.9%. Over the forecast period ranging from 2023 to 2033, the market is anticipated to gain traction at a CAGR of 5%, reaching an industry value of USD 6.6 billion. According to a Cleveland Clinic report, approximately 200,000 Americans suffer from unstable angina every year. Unstable angina is more prevalent among older people, men, and those who smoke, have high blood sugar levels, or have hypertension.
The primary factors driving the market growth are an augmentation in the number of patients being treated for unstable angina and the authorization of new therapeutics with high safety and effectiveness. Rivaroxaban, varespladib, and otamixaban are a few instances of new therapeutics that are presently in the late phases of clinical progression. If authorized, these products are predicted to be advertised at high prices. Nevertheless, a low adoption rate of therapeutic strategies in a generics-dominated industry would slow the expansion of the unstable angina therapeutics market.
If there is an artery obstruction or shrinking, the practitioner may suggest invasive surgery like angioplasty, and in severe instances, cardiac bypass surgery. The market for unstable angina therapeutics has tremendous growth potential, owing primarily to a rise in the number of people suffering from cardiac ailments, increased tobacco use, poor dietary habits, and lifestyle changes. Therefore, increasing awareness about lifestyle changes is also predicted to boost market growth.
As per one 2020 article, roughly 18 million individuals in the United States suffer from unstable angina. Furthermore, the Americas are expected to represent the majority of global percutaneous coronary interventions. As percutaneous coronary intervention (PCI) is growing more prevalent in the United States and Canada, that region is expected to be the leader in the unstable angina therapeutics industry in the forthcoming years. Because of the increasing prevalence of cardiovascular diseases, enhanced medical facilities, and increasing disposable income, Asia-Pacific is estimated to accelerate at the fastest pace. The Middle East and Africa market share are predicted to grow due to the significant recurrence of therapeutic intervention in Kuwait, Saudi Arabia, and the UAE.
Aspects such as the soaring prevalence of numerous cardiovascular disorders including Coronary Heart Disease (CHD), myocardial infarction, and strokes, in addition to the growing requirement for minimally invasive surgeries, are contributing to the expansion of the coronary artery bypass graft (CABG) surgery segment. Nonsteroidal anti-inflammatory drugs (NSAIDs) are growing in popularity due to variables such as the growing incidence of pain around the world, as well as an enhancement in the worldwide aging populations. Because of the high adoption rate of effective therapies for unstable angina patients, the hospital segment held the largest market share among end-user segments.
Leading healthcare practitioners in the market are employing a variety of therapeutic and combat strategies. These include a variety of measures such as pipeline research to develop effective drug applicants, in-house therapy sessions, and collaboration with healthcare technology providers to establish advanced therapeutics infrastructures.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | USD 4.05 billion |
| Anticipated Forecast Value (2033) | USD 6.6 billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Explore FMI!
Book a free demo
According to Future Market Insights, unstable angina therapeutics experienced a substantial boost from 2018 to 2022, with a CAGR of 4%. COVID-19 had become a significant public health concern in the historical period. In the past, unsuitable cautions against the usage of NSAID stimulants for COVID-19 patients with a higher likelihood of adverse impacts have been imposed. This caused widespread consternation among patient populations and the healthcare sector. As a result, COVID-19 had a significant impact on the consumption and prescription of various drugs for unstable angina in the global market.
Increasing medical prices will raise the economic strain on uninsured patients over the projected timeframe, causing individuals to migrate to developing countries where surgery costs less. This, in turn, is increasing the need for medical tourism in evolving countries. Among the main determinants predicted to propel the market in emerging economies over the forecast period are the presence of advantages like improved healthcare, lower surgical costs, and superior hospitality.
Global Geriatric Population Growth to steer Market Growth
As a result, the growing elderly population around the world is predicted to propel market growth. Based on an Administration on Aging (AoA) report, the number of people aged 65 and older in the United States was about 54.1 million in 2019, accounting for more than 16% of the total population.
There were approximately 30 million women and approximately 24.1 million men among them. By 2040, this population is predicted to account for 21.6% of the total in the United States. As a result, the growing geriatric population is predicted to drive the expansion of the unstable angina therapeutics market in the coming years.
Drugs Authorization by government drives Market Growth
The increasing number of medications approved by government agencies is expected to drive the growth of the unstable angina therapeutics market in the coming decades. Clopidogrel, for instance, is FDA-approved for the medical treatment of unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI).
Clopidogrel, when combined with aspirin, has historically been demonstrated to lower the probability of death, reoccurring heart attacks, or stroke in patient populations with unstable angina or a less severe cardiac attack.
Low Adoption Rate of Treatment and High Costs to Hinder Market Growth
Nevertheless, a low adoption rate of new treatments in a generics-dominated industry would slow the expansion of the unstable angina therapeutics market. Other attributes like patent expirations and the exorbitant prices of drug development may also impede market growth. For instance, a coronary artery bypass graft surgery costs an average of USD 54,000 - USD 148,400 in the United States.
Advanced Surgeries and Treatments Options drive the Regional Market Growth
Owing to the evolving guidelines related to patient treatment and management, North America is anticipated to dominate the unstable angina therapeutics market over the coming years. The occurrence of unstable angina is escalating in the United States, with nearly 1 million hospitalized patients having a primary diagnosis of unstable angina every year. As a result, this aspect is anticipated to contribute to industry growth.
Furthermore, North America is predicted to control the whole coronary artery bypass graft surgery market across the forthcoming years, driving future growth even further. For instance, as per data released by the Centers for Disease Control and Prevention in July 2022, 20.1 million Americans aged 20 and adults over the age were impacted by coronary heart disease in 2020. North America accounted for 45% market share in 2022.
Europe is the world's 2nd largest market for Unstable Angina Therapeutics
According to a recent article in Academic Group, Europe is the second largest industry for unstable angina therapeutics. Aspects including the accessibility of research grants, a burgeoning obese and patient citizenry, and the involvement of advanced economies like France, Italy, and Germany in the region all provide favorable backdrops for regional market expansion.
Unstable angina causes over 115,000 acute hospitalizations in the UK each year (200 per 100,000 population), with a substantial male predominance. In Europe, hospitalization rates for unstable angina outnumber those for ST-elevation myocardial infarction1. Before the introduction of modern treatment modalities, 15% of patients with unstable angina proceeded to a severe myocardial infarction, with total in-hospital mortality reaching 5%. Thus these factors are expected to propel the regional market.
Hospital Segment is Estimated to Hold the Largest Share
The hospital segment led the market in 2022, accounting for 46% of total revenue. Hospitals are commonly considered primary healthcare systems, and the patient population's preference for hospitals for the evaluation and treatment of chronic disorders is fuelling segment growth. Furthermore, the same segment is expected to grow at the fastest rate between 2023 and 2033.
Beta Blockers Segment is Estimated to Hold the Largest Share
The beta blockers segment is anticipated to expand at a CAGR of 4.4% during the projected timeline. Because of technological developments, massive expenditure, higher incidence and occurrence of cardiovascular diseases, and an aging population, the popularity of beta blockers has risen exponentially. Furthermore, the segment will benefit from a rising patient population and a lack of adequate treatment.
Various start-ups are launching advanced treatment procedures and drugs to drive market growth. For instance,
Key players in the Unstable Angina Therapeutics market are Bayer Healthcare, Sanofi, Anthera Pharmaceuticals, Ablynx, Saphnix Life Sciences, Copperhead Chemical, Medtronic, Enomark Kinetics, CDH Fine Chemical. Some of the latest developments are below,
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 4.05 billion |
| Anticipated Forecast Value (2033) | USD 6.6 billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment, End User, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, Indonesia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Bayer AG; Sanofi S.A; Anthera Pharmaceuticals; Ablynx; Saphnix Lifesciences; Copperhead Chemical; Medtronic; Enomark; Kinetics; CDH Fine Chemical |
| Customization | Available Upon Request |
The global market size to reach USD 6.6 million by 2033.
Bayer AG and Kinetics are the top key players.
The growth potential of the enterprise key management market is 5% through 2033
The low adoption of treatment rates is likely to limit market growth.
The hospital segment is highly preferred in the global market.
Pet DNA Testing Market Analysis by Animal Type, Sample Type, Test Type, End User and Region: Forecast for 2025 to 2035
Dental Practice Management Software Market Growth, Demand & Forecast 2025 to 2035
Dental Consumables Market Insights by Product, End-Users, and Region through 2035
Hyperpigmentation Treatment Market – Trends & Future Outlook 2025 to 2035
Idiopathic Pulmonary Fibrosis Management Market - Growth & Drug Advances 2025 to 2035
Hypopituitarism Diagnostics Market Outlook - Growth & Future Trends 2025 to 2035
Unstable Angina Therapeutics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
